Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cocktail of cancer drugs aims to outsmart relapsed myeloma

NCT ID NCT04643002

Recruiting now Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This umbrella trial tests the drug isatuximab (Sarclisa) combined with several newer agents, with or without dexamethasone, in adults whose multiple myeloma has returned or stopped responding to at least two prior treatments. About 258 participants will be assigned to different substudies to find the safest and most effective combinations. The goal is to improve response rates and offer more options for this hard-to-treat blood cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

isatuximab (Sarclisa) combined with dexamethasone, pomalidomide, belantamab mafodotin, or pegenzileukin

What this could lead to

If successful, this could offer new combination treatment options for people with multiple myeloma that has stopped responding to standard therapies.

What could go wrong

This is an early-phase trial with small groups testing different drug combos. Many experimental combinations may not work better than existing ones, and side effects could be serious.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLASMA CELL MYELOMA REFRACTORY

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Investigational Site Number : 0360001

    RECRUITING

    Richmond, Victoria, 3121, Australia

  • Investigational Site Number : 0360002

    RECRUITING

    Melbourne, Victoria, 3065, Australia

  • Investigational Site Number : 0360006

    RECRUITING

    Wollongong, New South Wales, 2500, Australia

  • Investigational Site Number : 2500001

    RECRUITING

    Nantes, 44093, France

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Investigational Site Number : 2500002

    RECRUITING

    Lille, 59037, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Investigational Site Number : 2500003

    RECRUITING

    Paris, Washington, 75013, France

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Investigational Site Number : 2500004

    RECRUITING

    Paris, 75015, France

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Investigational Site Number : 2760006

    RECRUITING

    Frankfurt, 60590, Germany

  • Investigational Site Number : 2760008

    RECRUITING

    Lübeck, 23562, Germany

  • Investigational Site Number : 3000001

    RECRUITING

    Athens, 115 28, Greece

  • Investigational Site Number : 3000002

    RECRUITING

    Athens, 106 76, Greece

  • Investigational Site Number : 3760001

    RECRUITING

    Tel Aviv, 6423906, Israel

  • Investigational Site Number : 3760002

    RECRUITING

    Jerusalem, 9112001, Israel

  • Investigational Site Number : 3760003

    RECRUITING

    Ramat Gan, 5262100, Israel

  • Investigational Site Number : 3800001

    RECRUITING

    Meldola, Reggio Emilia, 47014, Italy

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Investigational Site Number : 4100001

    RECRUITING

    Seoul, Seoul-teukbyeolsi, 03080, South Korea

  • Investigational Site Number : 4100002

    RECRUITING

    Seoul, Seoul-teukbyeolsi, 06351, South Korea

  • Investigational Site Number : 4100003

    RECRUITING

    Seoul, Seoul-teukbyeolsi, 06591, South Korea

  • Investigational Site Number : 4100004

    RECRUITING

    Seoul, Seoul-teukbyeolsi, 03722, South Korea

  • Investigational Site Number : 5780001

    RECRUITING

    Oslo, 0450, Norway

  • Puerto Rico Medical Research Center- Site Number : 8400005

    RECRUITING

    Hato Rey, Puerto Rico, 00917, Puerto Rico

  • Roswell Park Cancer Institute- Site Number : 8400008

    RECRUITING

    Buffalo, New York, 14263, United States

  • The Ohio State University- Site Number : 8400012

    RECRUITING

    Columbus, Ohio, 43210, United States

  • University of Illinois-Chicago - College of Medicine- Site Number : 8400007

    COMPLETED

    Chicago, Illinois, 60612, United States

  • University of Michigan Health System - Ann Arbor- Site Number : 8400004

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

  • Winship Cancer Institute of Emory University- Site Number : 8400010

    RECRUITING

    Atlanta, Georgia, 30322, United States